Inspyr Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 20, 2020 at 05:23 pm EST
Share
Inspyr Therapeutics, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced operating loss was USD 137,000 compared to USD 137,000 a year ago. Net income was USD 2.106 million compared to USD 421,000 a year ago. Basic earnings per share from continuing operations was USD 0.16 compared to USD 1.75 a year ago. Diluted eps - continuing operations was USD 0 compared to diluted loss per share from continuing operations of USD 0.07 a year ago. For the nine months, operating loss was USD 377,000 compared to USD 499,000 a year ago. Net income was USD 205,000 compared to net loss of USD 492,000 a year ago. Basic earnings per share from continuing operations was USD 0.03 compared to basic loss per share from continuing operations of USD 2.08 a year ago. Diluted eps - continuing operations was USD 0 compared to diluted loss per share from continuing operations of USD 2.08 a year ago.
Rebus Holdings, Inc. is a pharmaceutical company. The Company is focused on the research and development of targeted precision therapeutics for the treatment of cancer. The Company utilizes its proprietary delivery technology to enhance immuno-modulation for developing therapeutic outcomes. Its immune-oncology lead asset, RT-AR001, is an adenosine A2A receptor antagonist, is differentiated by its intratumoral delivery of nano- or microparticle formulations that allow for better tumor infiltration. Its patented portfolio of adenosine receptor antagonists provides treatment based on the specific adenosine targets found in each type of cancer. The adenosine receptor modulators include A2A, A2B and dual A2A/A2B antagonists, that have broad development applicability, including indications within immuno-oncology. It is also engaged in the manufacturing of platform delivery systems for nano- or microparticle formulations that are used in toxicology studies.
REBUS HOLDINGS, INC. 